Fighting Sars-CoV-2

SOLO COVID-19 is the evidence Oncodesign’s pharmacological expertise combined with our agility and societal commitment.

This new offering was rapidly spread out in 2020, to allow – with rigor and safety – the performance of specific in vitro and in vivo pharmacology studies to assess new preventive, therapeutic or vaccine approaches to the treatment of COVID-19.

In collaboration with our partners IDMIT and SEPIA from CEA, SOLO PoC Covid-19 offers an integrated panel of in vitro assays and animal models infected with Sars-CoV-2.

  • Biochemical assays for Spike S protein binding, Sars-CoV-2 viral protease activities, human ACE2 protein binding and human TMPRSS2 protease activity.
  • Infection tests of human and simian cells by the original Sars-CoV-2 variant and its variants (English, South African, Brazilian and Indian) to assess the potential of compounds on viral load, cytopathogenic effect, immune modulation and air-liquid interface.
  • Models of Sars-CoV-2 infection of transgenic mice, or non-lethal native infection of hamsters and non-human primates, to assess the preventive protective activity of new vaccines or the pharmacological efficacy of new therapeutic agents or repositioned compounds, integrating multiple analyses including imaging.
  • Severe inflammatory model of pulmonary fibrosis in mice, to assess the proof of concept of therapeutic solutions oriented in the management and treatment of post-acute respiratory distress syndrome.

Fix a meeting